Cargando…
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362531/ https://www.ncbi.nlm.nih.gov/pubmed/37390313 http://dx.doi.org/10.1182/bloodadvances.2023010270 |
Ejemplares similares
-
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia
por: Ilich, Anton, et al.
Publicado: (2022) -
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis
por: Pabinger, Ingrid, et al.
Publicado: (2017) -
Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607.
Publicado: (2023) -
Huynh A, Arnold DM, Michael JV, et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 2023;7(2):246-250.
Publicado: (2023) -
Vladimir Ilich Lenin : vida y obra
por: Zevin, V.
Publicado: (1974)